by According to Precedence Research, during the forecast period of 2022 to 2030, the global cancer diagnostics market is estimated to develop at a compound annual growth rate (CAGR) of 8.4%. The global cancer diagnostics market was valued at USD 124.96 billion in 2021, and it is predicted to exceed USD 258.54 billion by 2030. The study investigates several elements and their consequences on the growth of the cancer diagnostics market.
Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/1194
This report focuses on cancer diagnostics market volume and value at the global level, regional level and company level. From a global perspective, this report represents overall cancer diagnostics market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Middle East & Africa, Latin America, etc.
| Report Highlights | Details |
| Market Size | US$ 258.54 Billion by 2030 |
| Growth Rate | CAGR of 8.4% From 2022 to 2030 |
| Base Year | 2021 |
| Historic Data | 2017 to 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Test Type, Application |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
In-Depth Analysis on Competitive Landscape
The report sheds light on leading manufacturers of cancer diagnostics, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in the production of cancer diagnostics has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the cancer diagnostics market.
Some of the prominent players in the cancer diagnostics market include:
- Agilent Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Becton, Dickinson and Company
- GE Healthcare
- QIAGEN N.V.
- Abbott Laboratories, Inc.
- Roche Diagnostics
- Siemens Healthcare
- Philips Healthcare
- R. Bard, Inc.
- bioMérieux SA
- NeoGenomics Laboratories, Inc.
- Volpara Solutions Limited
- Hologic Inc.
- Canon Medical Systems Corporation
- PenRad Technologies Inc.
- BioNTech Diagnostics GmbH
- BioGenex
Ask Here For More Customization Study@ https://www.precedenceresearch.com/customization/1194
Segments Covered in the Report
By Product
- Consumables
- Antibodies
- Kits & Reagents
- Probes
- Other Consumables
- Instruments
- Pathology-based Instruments
- Slide Staining Systems
- Tissue Processing Systems
- Cell Processors
- PCR Instruments
- NGS Instruments
- Microarrays
- Other Pathology-based Instruments
- Imaging Instruments
- CT Systems
- Ultrasound Systems
- MRI Systems
- Mammography Systems
- Nuclear Imaging Systems
- Biopsy Instruments
By Technology
- IVD Testing
- Polymerase Chain Reaction (PCR)
- In Situ Hybridization (ISH)
- Immunohistochemistry (IHC)
- Next-generation Sequencing (NGS)
- Microarrays
- Flow Cytometry
- Immunoassays
- Other IVD Testing Technologies
- Imaging
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT)
- Positron Emission Tomography (PET)
- Mammography
- Ultrasound
- Biopsy Technique
By Application
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Lung Cancer
- Prostate Cancer
- Skin Cancer
- Blood Cancer
- Kidney Cancer
- Liver Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Others
By End Use
- Hospitals and Clinics
- Diagnostic Laboratories
- Diagnostic Imaging Centers
- Research Institutes
Regional Segmentation
- Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
- Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
- North America [United States, Canada, Mexico]
- South America [Brazil, Argentina, Columbia, Chile, Peru]
- Middle East & Africa [GCC, North Africa, South Africa]
Some of the important ones are:
- What can be the best investment choices for venturing into new product and service lines?
- What value propositions should businesses aim at while making new research and development funding?
- Which regulations will be most helpful for stakeholders to boost their supply chain network?
- Which regions might see the demand maturing in certain segments in near future?
- What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
- Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
- Which government regulations might challenge the status of key regional markets?
- How will the emerging political and economic scenario affect opportunities in key growth areas?
- What are some of the value-grab opportunities in various segments?
- What will be the barrier to entry for new players in the market?
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Diagnostics Market
5.1. COVID-19 Landscape: Cancer Diagnostics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Diagnostics Market, By Product
8.1. Cancer Diagnostics Market, by Product Type, 2022-2030
8.1.1. Consumables (Antibodies, Kits & Reagents, Probes, Other Consumables)
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Instruments (Pathology-based Instruments, Slide Staining Systems, Tissue Processing Systems, Cell Processors, Others)
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Imaging Instruments (CT Systems, Ultrasound Systems, MRI Systems, Mammography Systems, Nuclear Imaging Systems)
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Biopsy Instruments
8.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Cancer Diagnostics Market, By Technology
9.1. Cancer Diagnostics Market, by Technology, 2022-2030
9.1.1. IVD Testing (PCR, ISH, IHC, NGS, Microarrays, Flow Cytometry, Immunoassays)
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Imaging (MRI, CT, PET, Mammography, Ultrasound)
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Biopsy Technique
9.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Cancer Diagnostics Market, By Application
10.1. Cancer Diagnostics Market, by Application, 2022-2030
10.1.1. Breast Cancer
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Colorectal Cancer
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. Cervical Cancer
10.1.3.1. Market Revenue and Forecast (2019-2030)
10.1.4. Lung Cancer
10.1.4.1. Market Revenue and Forecast (2019-2030)
10.1.5. Prostate Cancer
10.1.5.1. Market Revenue and Forecast (2019-2030)
10.1.6. Skin Cancer
10.1.6.1. Market Revenue and Forecast (2019-2030)
10.1.7. Blood Cancer
10.1.7.1. Market Revenue and Forecast (2019-2030)
10.1.8. Kidney Cancer
10.1.8.1. Market Revenue and Forecast (2019-2030)
10.1.9. Liver Cancer
10.1.9.1. Market Revenue and Forecast (2019-2030)
10.1.10. Pancreatic Cancer
10.1.10.1. Market Revenue and Forecast (2019-2030)
10.1.11. Ovarian Cancer
10.1.11.1. Market Revenue and Forecast (2019-2030)
10.1.12. Others
10.1.12.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Cancer Diagnostics Market, By End Use
11.1. Cancer Diagnostics Market, by End Use, 2022-2030
11.1.1. Hospitals and Clinics
11.1.1.1. Market Revenue and Forecast (2019-2030)
11.1.2. Diagnostic Laboratories
11.1.2.1. Market Revenue and Forecast (2019-2030)
11.1.3. Diagnostic Imaging Centers
11.1.3.1. Market Revenue and Forecast (2019-2030)
11.1.4. Research Institutes
11.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 12. Global Cancer Diagnostics Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2019-2030)
12.1.2. Market Revenue and Forecast, by Technology (2019-2030)
12.1.3. Market Revenue and Forecast, by Application (2019-2030)
12.1.4. Market Revenue and Forecast, by End Use (2019-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.1.5.2. Market Revenue and Forecast, by Technology (2019-2030)
12.1.5.3. Market Revenue and Forecast, by Application (2019-2030)
12.1.5.4. Market Revenue and Forecast, by End Use (2019-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.1.6.2. Market Revenue and Forecast, by Technology (2019-2030)
12.1.6.3. Market Revenue and Forecast, by Application (2019-2030)
12.1.6.4. Market Revenue and Forecast, by End Use (2019-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.2. Market Revenue and Forecast, by Technology (2019-2030)
12.2.3. Market Revenue and Forecast, by Application (2019-2030)
12.2.4. Market Revenue and Forecast, by End Use (2019-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.5.2. Market Revenue and Forecast, by Technology (2019-2030)
12.2.5.3. Market Revenue and Forecast, by Application (2019-2030)
12.2.5.4. Market Revenue and Forecast, by End Use (2019-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.6.2. Market Revenue and Forecast, by Technology (2019-2030)
12.2.6.3. Market Revenue and Forecast, by Application (2019-2030)
12.2.6.4. Market Revenue and Forecast, by End Use (2019-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.7.2. Market Revenue and Forecast, by Technology (2019-2030)
12.2.7.3. Market Revenue and Forecast, by Application (2019-2030)
12.2.7.4. Market Revenue and Forecast, by End Use (2019-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.8.2. Market Revenue and Forecast, by Technology (2019-2030)
12.2.8.3. Market Revenue and Forecast, by Application (2019-2030)
12.2.8.4. Market Revenue and Forecast, by End Use (2019-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.2. Market Revenue and Forecast, by Technology (2019-2030)
12.3.3. Market Revenue and Forecast, by Application (2019-2030)
12.3.4. Market Revenue and Forecast, by End Use (2019-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.5.2. Market Revenue and Forecast, by Technology (2019-2030)
12.3.5.3. Market Revenue and Forecast, by Application (2019-2030)
12.3.5.4. Market Revenue and Forecast, by End Use (2019-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.6.2. Market Revenue and Forecast, by Technology (2019-2030)
12.3.6.3. Market Revenue and Forecast, by Application (2019-2030)
12.3.6.4. Market Revenue and Forecast, by End Use (2019-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.7.2. Market Revenue and Forecast, by Technology (2019-2030)
12.3.7.3. Market Revenue and Forecast, by Application (2019-2030)
12.3.7.4. Market Revenue and Forecast, by End Use (2019-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.8.2. Market Revenue and Forecast, by Technology (2019-2030)
12.3.8.3. Market Revenue and Forecast, by Application (2019-2030)
12.3.8.4. Market Revenue and Forecast, by End Use (2019-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.2. Market Revenue and Forecast, by Technology (2019-2030)
12.4.3. Market Revenue and Forecast, by Application (2019-2030)
12.4.4. Market Revenue and Forecast, by End Use (2019-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.5.2. Market Revenue and Forecast, by Technology (2019-2030)
12.4.5.3. Market Revenue and Forecast, by Application (2019-2030)
12.4.5.4. Market Revenue and Forecast, by End Use (2019-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.6.2. Market Revenue and Forecast, by Technology (2019-2030)
12.4.6.3. Market Revenue and Forecast, by Application (2019-2030)
12.4.6.4. Market Revenue and Forecast, by End Use (2019-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.7.2. Market Revenue and Forecast, by Technology (2019-2030)
12.4.7.3. Market Revenue and Forecast, by Application (2019-2030)
12.4.7.4. Market Revenue and Forecast, by End Use (2019-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.8.2. Market Revenue and Forecast, by Technology (2019-2030)
12.4.8.3. Market Revenue and Forecast, by Application (2019-2030)
12.4.8.4. Market Revenue and Forecast, by End Use (2019-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.5.2. Market Revenue and Forecast, by Technology (2019-2030)
12.5.3. Market Revenue and Forecast, by Application (2019-2030)
12.5.4. Market Revenue and Forecast, by End Use (2019-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.5.5.2. Market Revenue and Forecast, by Technology (2019-2030)
12.5.5.3. Market Revenue and Forecast, by Application (2019-2030)
12.5.5.4. Market Revenue and Forecast, by End Use (2019-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.5.6.2. Market Revenue and Forecast, by Technology (2019-2030)
12.5.6.3. Market Revenue and Forecast, by Application (2019-2030)
12.5.6.4. Market Revenue and Forecast, by End Use (2019-2030)
Chapter 13. Company Profiles
13.1. Agilent Technologies, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Thermo Fisher Scientific, Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Illumina, Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Becton, Dickinson and Company
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GE Healthcare
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. QIAGEN N.V.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Abbott Laboratories, Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Roche Diagnostics
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Siemens Healthcare
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Philips Healthcare
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
13.11. R. Bard, Inc.
13.11.1. Company Overview
13.11.2. Product Offerings
13.11.3. Financial Performance
13.11.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/1194
About Us
Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.
From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
